PTB
MCID: PLM001
MIFTS: 72

Pulmonary Tuberculosis (PTB)

Categories: Infectious diseases, Respiratory diseases

Aliases & Classifications for Pulmonary Tuberculosis

MalaCards integrated aliases for Pulmonary Tuberculosis:

Name: Pulmonary Tuberculosis 12 15 17
Tuberculosis, Pulmonary 75 44 72
Tuberculosis Pulmonary 55
Ptb 48

Classifications:



External Ids:

Disease Ontology 12 DOID:2957
ICD9CM 35 011 011.9 011.90
MeSH 44 D014397
NCIt 50 C26899
SNOMED-CT 68 81483001
ICD10 33 A15 A15.0
UMLS 72 C0041327

Summaries for Pulmonary Tuberculosis

Disease Ontology : 12 A tuberculosis that is a contagious disease located in lungs. The infection has symptom fever, has symptom cough, has symptom difficulty in breathing, has symptom inflammatory infiltrations, has symptom formation of tubercles, has symptom caseation, has symptom pleural effusion, and has symptom fibrosis.

MalaCards based summary : Pulmonary Tuberculosis, also known as tuberculosis, pulmonary, is related to miliary tuberculosis and lung disease, and has symptoms including fever, cough and pleural effusion. An important gene associated with Pulmonary Tuberculosis is IFNG (Interferon Gamma), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Calcium carbonate and Esomeprazole have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and liver, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 75 Tuberculosis (TB) is an infectious disease usually caused by Mycobacterium tuberculosis (MTB) bacteria.... more...

Related Diseases for Pulmonary Tuberculosis

Diseases related to Pulmonary Tuberculosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 995)
# Related Disease Score Top Affiliating Genes
1 miliary tuberculosis 32.6 TNF IL12RB1 IFNG ADA
2 lung disease 32.0 TNF TLR2 MBL2 IL10
3 pneumonia 31.8 TNF TLR2 MBL2 IL10
4 candidiasis 31.5 MBL2 IL10 IFNG
5 pleurisy 31.4 TNF IL2 IFNG ADA
6 acquired immunodeficiency syndrome 31.3 TNF IL2 IL10 IFNG
7 oral tuberculosis 31.3 TNF IL2
8 hepatitis a 31.2 TNF IL10 IFNG
9 cryptococcosis 31.1 MBL2 IL4 IFNG
10 pulmonary sarcoidosis 31.1 TNF IL2 IL18 IFNG
11 erythema multiforme 31.1 TNF IL2 IFNG
12 multidrug-resistant tuberculosis 31.1 VDR TNF SLC11A1 INHA IL10
13 aspergillosis 31.0 TNF TLR2 MBL2 IL4 IL10 IFNG
14 pericarditis 31.0 TNF IFNG ADA
15 leprosy 3 31.0 TNF TLR2 SLC11A1 IL2 IL10 IFNG
16 human immunodeficiency virus infectious disease 31.0 TNF IL2 IL10 IFNG
17 interstitial lung disease 31.0 TNF IL4 IL10 IFNG
18 gastrointestinal system disease 31.0 TNF IL2 IL10 IFNG
19 herpes zoster 30.9 IL2 IL10 IFNG
20 pleural tuberculosis 30.9 TNF IL18 IFNG ADA
21 tuberculous peritonitis 30.9 TNF IFNG ADA
22 endocarditis 30.9 TNF TLR2 IL10
23 bronchiolitis 30.8 TNF IL4 IL10 IFNG
24 bronchiolitis obliterans 30.8 TNF IL10 IFNG
25 meningitis 30.8 TNF TLR2 MBL2 IL10 IFNG ADA
26 peritonitis 30.8 TNF TLR2 IL10 ADA
27 mouth disease 30.8 VDR TNF IL10 IFNG
28 bronchial disease 30.8 TNF IL4 IL10 IFNGR1
29 uveitis 30.8 TNF IL4 IL10 IFNG
30 coccidioidomycosis 30.8 MBL2 IL10 IFNGR1
31 hematopoietic stem cell transplantation 30.8 TNF IL2 IL10 IFNG
32 measles 30.8 TLR2 IL4 IL2 IFNG
33 immune deficiency disease 30.7 IL4 IL2 IL12RB1 IL10 IFNGR1
34 mycobacterium fortuitum 30.7 IL12RB1 IFNGR1
35 posterior uveitis 30.7 TNF IL2 IFNG
36 ige responsiveness, atopic 30.7 IL4 IL10 IFNG
37 echinococcosis 30.7 TNF TLR2 IL10 IFNG HLA-DRB1
38 panuveitis 30.7 TNF IL10 HLA-DRB1
39 tuberculous meningitis 30.7 TNF TLR2 NAT2 ADA
40 conjunctivitis 30.7 IL4 IL2 IFNG
41 crohn's disease 30.7 TNF SLC11A1 IL10 HP
42 toxoplasmosis 30.6 TNF TLR2 IL4 IL10 IFNG
43 neuritis 30.6 TNF IL4 IFNG
44 osteomyelitis 30.6 TNF IL10 IFNGR1 IFNG
45 chronic graft versus host disease 30.6 TNF IL10 IFNG
46 tonsillitis 30.6 TNF IL4 IL2 IFNG
47 arthritis 30.5 TNF IL18 IL10 IFNG HLA-DRB1
48 intestinal disease 30.5 TNF IL2 IL10
49 prosthetic joint infection 30.5 TLR2 MBL2
50 berylliosis 30.5 IL2 IFNG HLA-DRB1

Comorbidity relations with Pulmonary Tuberculosis via Phenotypic Disease Network (PDN):


Acute Cystitis Bronchiectasis
Bronchitis Deficiency Anemia
Heart Disease Iron Deficiency Anemia
Pleural Tuberculosis Postinflammatory Pulmonary Fibrosis
Protein-Energy Malnutrition Respiratory Failure

Graphical network of the top 20 diseases related to Pulmonary Tuberculosis:



Diseases related to Pulmonary Tuberculosis

Symptoms & Phenotypes for Pulmonary Tuberculosis

Symptoms:

12
  • fever
  • cough
  • pleural effusion
  • difficulty in breathing
  • inflammatory infiltrations
  • formation of tubercles
  • caseation
  • fibrosis

UMLS symptoms related to Pulmonary Tuberculosis:


hemoptysis

MGI Mouse Phenotypes related to Pulmonary Tuberculosis:

46 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.42 ADA HP IFNG IFNGR1 IL10 IL12B
2 homeostasis/metabolism MP:0005376 10.41 ADA HP IFNG IFNGR1 IL10 IL12B
3 immune system MP:0005387 10.39 ADA HP IFNG IFNGR1 IL10 IL12B
4 digestive/alimentary MP:0005381 10.35 ADA IFNG IFNGR1 IL10 IL12B IL18
5 cardiovascular system MP:0005385 10.34 ADA HP IFNG IFNGR1 IL10 IL18
6 cellular MP:0005384 10.33 ADA HP IFNG IFNGR1 IL10 IL18
7 growth/size/body region MP:0005378 10.32 ADA IFNG IL10 IL12B IL12RB1 IL18
8 behavior/neurological MP:0005386 10.27 IFNG IFNGR1 IL10 IL18 IL2 NAT2
9 endocrine/exocrine gland MP:0005379 10.22 ADA IFNG IFNGR1 IL10 IL2 IL4
10 mortality/aging MP:0010768 10.21 ADA HP IFNG IFNGR1 IL10 IL12B
11 liver/biliary system MP:0005370 10.1 ADA HP IFNG IFNGR1 IL10 IL2
12 integument MP:0010771 10.09 IFNG IFNGR1 IL10 IL18 IL4 P2RX7
13 neoplasm MP:0002006 10.02 HP IFNG IFNGR1 IL10 IL12B IL2
14 renal/urinary system MP:0005367 9.86 ADA HP IFNG IFNGR1 IL4 MBL2
15 reproductive system MP:0005389 9.85 ADA IFNG IFNGR1 IL10 IL2 IL4
16 respiratory system MP:0005388 9.56 ADA IFNG IL10 IL12B IL2 IL4
17 skeleton MP:0005390 9.36 ADA IFNG IFNGR1 IL10 IL12B IL4

Drugs & Therapeutics for Pulmonary Tuberculosis

Drugs for Pulmonary Tuberculosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 250)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Calcium carbonate Approved, Investigational Phase 4 471-34-1
2
Esomeprazole Approved, Investigational Phase 4 119141-88-7, 161796-78-7, 161973-10-0 9568614 4594
3 Immunologic Factors Phase 4
4 Antiparasitic Agents Phase 4
5 Antiprotozoal Agents Phase 4
6 interferons Phase 4
7 Interferon-gamma Phase 4
8 Antiviral Agents Phase 4
9 Cytochrome P-450 Enzyme Inhibitors Phase 4
10 Renal Agents Phase 4
11 Anti-Infective Agents, Urinary Phase 4
12 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
13 Immunosuppressive Agents Phase 4
14 Benzonidazole Phase 4
15 Antacids Phase 4
16 Gastrointestinal Agents Phase 4
17 Anti-Ulcer Agents Phase 4
18 Proton Pump Inhibitors Phase 4
19
Zinc sulfate Approved, Investigational Phase 3 7733-02-0
20
Didanosine Approved Phase 3 69655-05-6 50599
21
Nitric Oxide Approved Phase 3 10102-43-9 145068
22
Cycloserine Approved Phase 2, Phase 3 68-41-7 6234 401
23
Aminosalicylic Acid Approved Phase 2, Phase 3 65-49-6 4649
24
Zinc Approved, Investigational Phase 3 7440-66-6 32051
25
leucovorin Approved Phase 3 58-05-9 143 6006
26
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
27
Hydroxocobalamin Approved Phase 3 13422-51-0 11953898 15589840
28
Nicotinamide Approved, Investigational Phase 3 98-92-0 936
29
Copper Approved, Investigational Phase 3 7440-50-8 27099
30
Nicotine Approved Phase 3 54-11-5 942 89594
31
Methylcobalamin Approved, Experimental, Investigational Phase 3 13422-55-4
32
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
33
Prothionamide Approved, Investigational Phase 2, Phase 3 14222-60-7 666418
34
Kanamycin Approved, Investigational, Vet_approved Phase 2, Phase 3 59-01-8, 8063-07-8 6032
35
Azithromycin Approved Phase 3 83905-01-5 447043 55185
36
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
37
Isoniazid Approved, Investigational Phase 3 54-85-3 3767
38
Ethambutol Approved Phase 3 74-55-5 3279 14052
39
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
40
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
41
Pyrazinamide Approved, Investigational Phase 3 98-96-4 1046
42
Rifampicin Approved Phase 3 13292-46-1 5381226 5458213
43
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
44
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
45
Polyestradiol phosphate Approved Phase 3 28014-46-2
46
Permethrin Approved, Investigational Phase 3 52645-53-1 40326
47
Rifapentine Approved, Investigational Phase 3 61379-65-5 6323497
48
Bedaquiline Approved Phase 3 843663-66-1
49
Linezolid Approved, Investigational Phase 3 165800-03-3 441401
50
Clofazimine Approved, Investigational Phase 3 2030-63-9 2794

Interventional clinical trials:

(show top 50) (show all 258)
# Name Status NCT ID Phase Drugs
1 The Impact of the Simple Verbal Intervention for Adequately Collecting Sputum and the Acceptable Specimen Based on Gram Stain, on the Results of Sputum Acid-fast Bacilli Smear Testing Unknown status NCT01135043 Phase 4
2 New Super-short Course Regimen for Retreatment Pulmonary Tuberculosis Unknown status NCT02331823 Phase 4 Isoniazid Aminosalicylate Tablets;Streptomycin injectable
3 International Multicenter Trial for the Evaluation of a Four-Drug Fixed Dose Combined Tablet Daily in the Initial Intensive Phase of Chemotherapy Followed by a Two-Drug Fixed Dose Combined Tablet Three Times a Week in the Continuation Phase for the Treatment of Pulmonary Tuberculosis Unknown status NCT00216333 Phase 4 combined fixed dose combination
4 Shortened Regimens for First Diagnosed Smear Positive Drug Susceptible Pulmonary Tuberculosis: a Randomised Controlled Non-inferiority Trial Unknown status NCT02901288 Phase 4 Isoniazid;Rifampicin;Pyrazinamide;Ethambutol;Levofloxacin
5 Effect of Vitamin D as Adjunctive Therapy in Patients With Pulmonary Evolution Tuberculosis in the National Institute of Respiratory Diseases Unknown status NCT02464683 Phase 4
6 Effect of Supplementary Vitamin D in Patients With Diabetes Mellitus and Pulmonary Tuberculosis (EVIDENT Study): a Randomized, Double Blind, Controlled Trial Unknown status NCT02169570 Phase 4
7 Different Reintroduction Regimens of Antituberculosis Drugs After Development of Hepatitis During Anti-tuberculosis Treatment Unknown status NCT01395654 Phase 4 isoniazid, rifampin, pyrazinamide
8 Randomized Trial for Pharmacogenomics-based Tuberculosis Therapy (RT-PGTT) Completed NCT00298870 Phase 4 Isoniazid;isoniazed
9 Multicenter Open Non-Comparative Clinical Study to Evaluate the Efficacy and Safety of Three Months TAVANIC Course (Levofloxacin) in Combine Treatment of Multi-Drug-Resistant Tuberculosis (MDR-TB) Completed NCT00495339 Phase 4 Levofloxacin
10 Pilot Roll Out of the Xpert MTB/Rif for the Diagnosis of Pulmonary Tuberculosis in Two Municipalities in Brazil: a Stepped Wedge Trial Completed NCT01363765 Phase 4
11 A Randomised Control Trial on the Effectiveness of Three Modalities of Tuberculosis Treatment Supervision Under DOTS Strategy in Ethiopia. Completed NCT00939419 Phase 4
12 Cost-effectiveness of Quantiferon Gold in VITRO Test of T-lymphocytic Response for Detection of Latent Tuberculosis in At-risk Healthcare Workers Completed NCT00797836 Phase 4
13 Investigation of a Novel Approach to Improve Adherence to Treatment and Treatment Success Rates for Tuberculosis Patients in Senegal Completed NCT00412009 Phase 4
14 Optimization of Sampling Procedure for PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease Treated With Benznidazole in Aiquile, Bolivia Completed NCT01678599 Phase 4 Benznidazole
15 Primary Prophylaxis for Prevention of TB in Prison's Populations Recruiting NCT03028129 Phase 4 Isoniazid 900 milligrams;Placebo
16 Secondary Prevention With Long-term Oral Esomeprazole for Peptic Ulcer Recurrence and Rebleeding in High-risk Rockall Scores ≥ 6 Patients Recruiting NCT02456012 Phase 4 oral esomeprazole 20 mg twice daily;oral esomeprazole 20 mg once daily
17 Rapid Detection of Rifampin and Isoniazid Resistance by PCR Before Tuberculosis (TB) Treatment Initiation: a National Multicenter Randomized Clinical Trial Active, not recruiting NCT02231229 Phase 4 conventional therapy
18 Pilot Clinical Trial of PRS TB Regimen I - Phase II Enrolling by invitation NCT03561753 Phase 4 Group A (the standard 2HRZE/4HR regimen);Group B (New short course PRS regimen, 4EZ(high dose)PtoCfz)
19 A Randomised Open-Label Controlled Trial of a 4-Month Gatifloxacin-Containing Regimen Versus Standard Regimen for the Treatment of Adult Patients With Pulmonary Tuberculosis Unknown status NCT00216385 Phase 3 Gatifloxacin combined regimen
20 A Randomized, Double-Blind, Active Drug Controlled Study to Assess the Efficacy of HUEXC030 as Add-on Excipient to Eradicate Anti-Tuberculosis Drugs Induced Liver Injury in Subjects With Pulmonary Tuberculosis Unknown status NCT02467608 Phase 2, Phase 3 Isoniazid with HUEXC030 and RZE;HRZE
21 Efficacy of Oral Zinc Administration as an Adjunct Therapy in Category I Pulmonary Tuberculosis Along With Assessment of Immunological Parameters (Double-blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial Unknown status NCT00698386 Phase 3
22 Characterization of Immune Responses in Treatment-induced Latency in Pulmonary Tuberculosis Unknown status NCT01154959 Phase 3 Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol
23 Role of Oral Vitamin D as an Adjunct Therapy in Category I Pulmonary Tuberculosis Along With Assessment of Immunological Parameters. (Double-blind, Randomized, Placebo-Controlled, Clinical Trial) Unknown status NCT00507000 Phase 3 Cholecalciferol;Lactose granules
24 Evaluation of Safety and Efficacy of Two Different Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment in Patients With HIV-1 and Tuberculosis Unknown status NCT00332306 Phase 3 Didanosine, Lamivudine, Efavirenz;Didanosine, Lamivudine, Nevirapine
25 Trial of Adjunctive Vitamin D in Tuberculosis Treatment Completed NCT00419068 Phase 3 Cholecalciferol;Migliol Placebo Oil
26 A Phase 3 Open-Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of the Combination of Moxifloxacin Plus PA-824 Plus Pyrazinamide After 4 and 6 Months of Treatment in Adult Subjects With Drug-Sensitive Smear-Positive Pulmonary Tuberculosis and After 6 Months of Treatment in Adult Subjects With Multi-Drug Resistant, Smear-Positive Pulmonary Tuberculosis. Completed NCT02342886 Phase 3 Moxifloxacin;PA-824;Pyrazinamide;HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination);HR (rifampicin plus isoniazid combination tablets)
27 Phase 3 Trial of Oral L-arginine and / or Vitamin D as Adjunctive Therapies in Pulmonary Tuberculosis in Papua Province, Indonesia. Completed NCT00677339 Phase 3 L-arginine;Vitamin D;Placebo L-arginine;Placebo Vitamin D
28 A Double Blind, Randomized, Parallel, Placebo Control Design Study to Determine the Effect of Addition of Vitamin D to Conventional Anti TB Therapy Completed NCT00366470 Phase 3 A. 100,000 IU Cholecalciferol per dose of 3.3ml
29 Adjunct Vitamin A Therapy for Tuberculosis and HIV/AIDS Completed NCT00057434 Phase 3 multivitamin
30 Efficacy and Safety Study of Immunomodulator (Mycobacterium w) as an Adjunct Therapy in Category-II Pulmonary Tuberculosis Along With Assessment of Immunological Parameters Completed NCT00265226 Phase 3
31 Efficacy and Safety of Immunomodulator (Mycobacterium w.) as an Adjunct Therapy in Category I Pulmonary Tuberculosis and Along With Assessment of Immunological Parameters Completed NCT00341328 Phase 3
32 Micronutrient Supplementation in Conjunction With Standard Anti-Tuberculosis Therapy in Paediatric (6 Months-15 Years) New Pulmonary Tuberculosis Patients Completed NCT00801606 Phase 3 Zinc;Micronutrient without zinc;Micronutrient with zinc;Placebo
33 Impact of a Package of Intensive Smoking-cessation Interventions Versus Smoking-cessation Advice on Outcomes in Smear-positive Patients With Pulmonary Tuberculosis; a Randomised Controlled Trial (STB_RCT). Completed NCT01517022 Phase 3 nicotine replacement therapy
34 The Treatment of Pulmonary Mycobacterium Tuberculosis in HIV Infection Completed NCT00001033 Phase 3 Ethambutol hydrochloride;Isoniazid;Pyrazinamide;Pyridoxine hydrochloride;Levofloxacin;Rifampin
35 A Randomised Placebo - Controlled Double Blind Trial Comparing 1) a Two Month Intensive Phase of Ethambutol, Moxifloxacin, Rifampicin, Pyrazinamide Versus the Standard Regimen (Ethambutol, Isoniazid, Rifampicin, Pyrazinamide) and 2) a Treatment Shortening Regimen Comparing Two Months Moxifloxacin, Isoniazid, Rifampicin, Pyrazinamide Followed by Two Months Moxifloxacin, Isoniazid, Rifampicin Versus the Standard Regimen (Two Months Ethambutol, Isoniazid, Rifampicin, Pyrazinamide Followed by Four Months Isoniazid and Rifampicin) for the Treatment of Adults With Pulmonary Tuberculosis Completed NCT00864383 Phase 3 Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin
36 Optimization of the TB Treatment Regimen Cascade Completed NCT02153528 Phase 3 double rimfampicin;Standard TB treatment
37 A Randomized Controlled Clinical Trial Comparing Daily Vs. Intermittent 6 - Month Short Course Chemotherapy in Reducing Failures & Emergence of Acquired Rifampicin Resistance (ARR) in Patients With HIV and Pulmonary Tuberculosis Completed NCT00933790 Phase 3 ATT (Ethambutol, Pyrazinamide, INH, Rifampicin)
38 The Role of Nutritional Support and Diabetes During Treatment of Pulmonary TB: Two Randomized Nutritional Supplementation Trials in Tanzania Completed NCT00311298 Phase 3
39 Trial of Vitamin D in HIV Progression Completed NCT01798680 Phase 3
40 A Multi-centric Study on Treatment of Abdominal Tuberculosis (Intestinal or Peritoneal): A Randomized Controlled Trial to Compare the 6 Months of Cat I Treatment With 9 Months of Cat I Treatment (Extension for 3 Months) in Abdominal Tuberculosis Under the Revised National Tuberculosis Control Program Completed NCT01124929 Phase 3 RNTCP Category I treatment for 6 months;RNTCP Category I treatment for 9months
41 A Randomized Control Trial Of High-Dose Isoniazid Adjuvant Therapy For Multidrug Resistant Tuberculosis Completed NCT00513396 Phase 2, Phase 3 Isoniazid;Placebo
42 DARDAR Health Project (Disseminated Tuberculosis and HIV Infection) Completed NCT00052195 Phase 2, Phase 3
43 A Prospective Study of Shortening the Duration of Standard Short Course Chemotherapy From 6 Months to 4 Months in HIV-non-infected Patients With Fully Drug-Susceptible, Non-cavitary Pulmonary Tuberculosis With Negative Sputum Cultures After 2 Months of Anti-TB Treatment Completed NCT00130247 Phase 3 Ethambutol;Isoniazid;Pyrazinamide;Rifampin
44 An Open-Label, Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of a 4-month Treatment of Bedaquiline Plus Pretomanid Plus Moxifloxacin Plus Pyrazinamide (BPaMZ) Compared to a 6-month Treatment of HRZE/HR (Control) in Adult Participants With Drug-Sensitive Smear-Positive Pulmonary Tuberculosis (DS-TB) and a 6-month Treatment of BPaMZ in Adult Participants With Drug Resistant, Smear-Positive Pulmonary Tuberculosis (DR-TB) Recruiting NCT03338621 Phase 2, Phase 3 Pretomanid;Bedaquiline;Moxifloxacin;Pyrazinamide;HRZE;HR
45 Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis Recruiting NCT03474198 Phase 2, Phase 3 Rifampicin;Isoniazid;Pyrazinamide;Ethambutol;Linezolid;Clofazimine;Rifapentine;Levofloxacin;Bedaquiline;Rifampicin
46 An International Multicentre Controlled Clinical Trial to Evaluate 1200mg and 1800mg Rifampicin Daily for Four Months in the Reduction of the Duration of Standard Treatment of Pulmonary Tuberculosis Recruiting NCT02581527 Phase 3 Rifampicin 1200mg;Rifampicin 1800mg;4FDC
47 A Phase 3 Partially-blinded, Randomized Trial Assessing the Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary Infection of Either Extensively Drug-resistant Tuberculosis (XDR-TB), Pre-XDR-TB or Treatment Intolerant or Non-responsive Multi-drug Resistant Tuberculosis (MDR-TB) Recruiting NCT03086486 Phase 3 Pretomanid;Linezolid;Bedaquiline;Placebo Linezolid
48 A Randomised, Controlled, Open-Label, Phase II-III Trial to Evaluate the Safety and Efficacy of Regimens Containing Bedaquiline and Pretomanid for the Treatment of Adult Patients With Pulmonary Multidrug Resistant Tuberculosis Recruiting NCT02589782 Phase 2, Phase 3 Bedaquiline;Pretomanid;Moxifloxacin;Linezolid;Clofazimine;Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.
49 A Multicenter Phase II/III Double-Blind, Randomized, Placebo Controlled Study To Evaluate The Efficacy And Safety Of VPM1002 In The Prevention Of Tuberculosis (TB) Recurrence In Pulmonary TB Patients After Successful TB Treatment In India Recruiting NCT03152903 Phase 2, Phase 3
50 Randomised Controlled Clinical Trial Investigating Benefits of Using Response to Broad Spectrum Antibiotics as an Exclusion Diagnostic for Tuberculosis (TB) in Primary Care Adult Patients Versus Risk of Antimicrobial Resistance (AMR) Recruiting NCT03545373 Phase 3 Azithromycin;Amoxicillin

Search NIH Clinical Center for Pulmonary Tuberculosis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Betamethasone
Ethambutol
Prednisolone
Pyrazinamide

Cochrane evidence based reviews: tuberculosis, pulmonary

Genetic Tests for Pulmonary Tuberculosis

Anatomical Context for Pulmonary Tuberculosis

MalaCards organs/tissues related to Pulmonary Tuberculosis:

41
Lung, Testes, Liver, T Cells, Heart, Skin, Lymph Node

The Foundational Model of Anatomy Ontology organs/tissues related to Pulmonary Tuberculosis:

19
Lungs

Publications for Pulmonary Tuberculosis

Articles related to Pulmonary Tuberculosis:

(show top 50) (show all 30119)
# Title Authors PMID Year
1
Role of interferon-gamma release assays in the diagnosis of pulmonary tuberculosis in patients with advanced HIV infection. 9 38
20302657 2010
2
Association of reduced tumor necrosis factor alpha, gamma interferon, and interleukin-1beta (IL-1beta) but increased IL-10 expression with improved chest radiography in patients with pulmonary tuberculosis. 9 38
20007364 2010
3
Interferon gamma gene +874A/T polymorphism and intracellular interferon gamma expression in pulmonary tuberculosis. 9 38
20004112 2010
4
Association between FokI polymorphism in vitamin D receptor gene and susceptibility to spinal tuberculosis in Chinese Han population. 9 38
20430254 2010
5
P2X7 gene polymorphisms and risk assessment for pulmonary tuberculosis in Asian Indians. 9 38
20164546 2010
6
[Development and use of a domestic test system for diagnosis of tuberculous infection on the basis of quantitative analysis of interferon-gamma induction in whole blood samples in vitro, by using specific recombinant antigens]. 9 38
20201379 2010
7
Variants in toll-like receptors 2 and 9 influence susceptibility to pulmonary tuberculosis in Caucasians, African-Americans, and West Africans. 9 38
19771452 2010
8
Vitamin D receptor homozygote mutant tt and bb are associated with susceptibility to pulmonary tuberculosis in the Iranian population. 9 38
19482503 2010
9
Rapid diagnosis of active pulmonary tuberculosis in the elderly using enzyme-linked immunospot assay for interferon-gamma. 9 38
20121995 2009
10
Infection with Mycobacterium tuberculosis Beijing genotype strains is associated with polymorphisms in SLC11A1/NRAMP1 in Indonesian patients with tuberculosis. 9 38
19863441 2009
11
BCG vaccination reduces risk of infection with Mycobacterium tuberculosis as detected by gamma interferon release assay. 9 38
19715782 2009
12
Diagnosis of pulmonary tuberculosis among dialysis patients by enzyme-linked immunospot assay for interferon-gamma. 9 38
19474277 2009
13
Allelic polymorphism of cytokine genes during pulmonary tuberculosis. 9 38
20027321 2009
14
Engagement of Toll-like receptor 2 on CD4(+) T cells facilitates local immune responses in patients with tuberculous pleurisy. 9 38
19552525 2009
15
Plasma 1,25 dihydroxy vitamin D3 level and expression of vitamin d receptor and cathelicidin in pulmonary tuberculosis. 9 38
19219539 2009
16
Adenosine deaminase activity and its isoenzymes in the sputum of patients with pulmonary tuberculosis. 9 38
19460251 2009
17
[Case of pulmonary tuberculosis with miliary granules, mediastinal lymph node enlargement and elevation of soluble interleukin-2 receptor]. 9 38
19588853 2009
18
[A study on the haplotype of the solute carrier family 11 member 1 gene in Tibetan patients with pulmonary tuberculosis in China]. 9 38
19799071 2009
19
Analysis of discordance between the tuberculin skin test and the interferon-gamma release assay. 9 38
19335949 2009
20
Role played by human mannose-binding lectin polymorphisms in pulmonary tuberculosis. 9 38
19199550 2009
21
[A case of pulmonary tuberculosis and tuberculous pleuritis during treatment with etanercept for rheumatoid arthritis]. 9 38
19260544 2009
22
Effect of 1,25 dihydroxyvitamin D3 on intracellular IFN-gamma and TNF-alpha positive T cell subsets in pulmonary tuberculosis. 9 38
19091593 2009
23
Regulatory role of 1, 25-dihydroxyvitamin D3 and vitamin D receptor gene variants on intracellular granzyme A expression in pulmonary tuberculosis. 9 38
19014932 2009
24
[Modulatory effect of isoniazid and rifampicin in vitro on cytokine secretion in pulmonary tuberculosis]. 9 38
19697859 2009
25
Compartmentalized bronchoalveolar IFN-gamma and IL-12 response in human pulmonary tuberculosis. 9 38
18848499 2009
26
Markedly-elevated serum CA125 in a woman with pulmonary tuberculosis. 9 38
19224069 2009
27
[Diagnostic value of interferon-gamma in the serum of patients with pulmonary tuberculosis and lung cancer diseases]. 9 38
19810179 2009
28
[In vitro interferon-gamma induction in whole blood samples is a test for tuberculous infection in children and adolescents]. 9 38
19642569 2009
29
The impact of HIV infection and CD4 cell count on the performance of an interferon gamma release assay in patients with pulmonary tuberculosis. 9 38
19156218 2009
30
Impaired gamma interferon response to Mycobacterium vaccae antigens in patients with cavitary pulmonary tuberculosis. 9 38
18596204 2008
31
Differential expression of interleukin-4 (IL-4) and IL-4 delta 2 mRNA, but not transforming growth factor beta (TGF-beta), TGF-beta RII, Foxp3, gamma interferon, T-bet, or GATA-3 mRNA, in patients with fast and slow responses to antituberculosis treatment. 9 38
18579694 2008
32
Interleukin-12 receptor beta1 polymorphisms and nontuberculous mycobacterial lung diseases. 9 38
18493823 2008
33
Cytokine gene polymorphisms and cytokine levels in pulmonary tuberculosis. 9 38
18522869 2008
34
Regulatory role of promoter and 3' UTR variants of vitamin D receptor gene on cytokine response in pulmonary tuberculosis. 9 38
18231846 2008
35
A new protocol for multiple inhalation of IFN-gamma successfully treats MDR-TB: a case study. 9 38
18492330 2008
36
Comparison of sensitivities of two commercial gamma interferon release assays for pulmonary tuberculosis. 9 38
18400912 2008
37
Enhancement of diagnostic efficiency by a gamma interferon release assay for pulmonary tuberculosis. 9 38
18400971 2008
38
Regulatory region polymorphisms of vitamin D receptor gene in pulmonary tuberculosis patients and normal healthy subjects of south India. 9 38
18397302 2008
39
Immune response to Nocardia brasiliensis extracellular antigens in patients with mycetoma. 9 38
18302006 2008
40
Accuracy of an interferon-gamma release assay to detect active pulmonary and extra-pulmonary tuberculosis. 9 38
18284831 2008
41
[Plasma levels of cytokines in patients with active infiltrative pulmonary tuberculosis]. 9 38
18819336 2008
42
SLC11A1 (formerly NRAMP1) polymorphisms associated with multidrug-resistant tuberculosis. 9 38
17950034 2008
43
[Modulation of an antituberculous immune response in vitro, by using antigen-activated dendritic cells]. 9 38
18368774 2008
44
Validity of the CA125 level in the differential diagnosis of pulmonary tuberculosis. 9 38
18219138 2008
45
Diagnostic accuracy of cytokine levels (TNF-alpha, IL-2 and IFN-gamma) in bronchoalveolar lavage fluid of smear-negative pulmonary tuberculosis patients. 9 38
17975298 2008
46
CD14 C(-159)T polymorphism is a risk factor for development of pulmonary tuberculosis. 9 38
18008256 2007
47
Genetic polymorphisms in alveolar macrophage response-related genes, and risk of silicosis and pulmonary tuberculosis in Chinese iron miners. 9 38
17223386 2007
48
Rifampin levels, interferon-gamma release and outcome in complicated pulmonary tuberculosis. 9 38
17890156 2007
49
Polymorphisms of interferon-gamma and interferon-gamma receptor 1 genes and pulmonary tuberculosis in Koreans. 9 38
17986123 2007
50
Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. 9 38
17950035 2007

Variations for Pulmonary Tuberculosis

Expression for Pulmonary Tuberculosis

LifeMap Discovery
Genes differentially expressed in tissues of Pulmonary Tuberculosis patients vs. healthy controls: 35 (show all 44)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 GBP6 guanylate binding protein family, member 6 Blood + 4.38 0.000
2 ANKRD22 ankyrin repeat domain 22 Blood + 4.04 0.000
3 PDCD1LG2 programmed cell death 1 ligand 2 Blood + 4.03 0.000
4 RLTPR RGD motif, leucine rich repeats, tropomodulin domain and proline-rich containing Blood - 3.89 0.000
5 CD274 CD274 molecule Blood + 3.87 0.000
6 CD248 CD248 molecule, endosialin Blood - 3.84 0.000
7 SPIB Spi-B transcription factor (Spi-1/PU.1 related) Blood - 3.81 0.000
8 LRRN3 leucine rich repeat neuronal 3 Blood - 3.61 0.000
9 LINC00668 long intergenic non-protein coding RNA 668 Blood + 3.60 0.000
10 C1QC complement component 1, q subcomponent, C chain Blood + 3.56 0.000
11 CR1 complement component (3b/4b) receptor 1 (Knops blood group) Blood + 3.54 0.000
12 AEBP1 AE binding protein 1 Blood - 3.53 0.000
13 KREMEN1 kringle containing transmembrane protein 1 Blood + 3.49 0.000
14 CACNA1E calcium channel, voltage-dependent, R type, alpha 1E subunit Blood + 3.46 0.000
15 LGALSL lectin, galactoside-binding-like Blood - 3.43 0.000
16 BATF2 basic leucine zipper transcription factor, ATF-like 2 Blood + 3.42 0.000
17 PLEKHB1 pleckstrin homology domain containing, family B (evectins) member 1 Blood - 3.40 0.000
18 CD22 CD22 molecule Blood - 3.38 0.000
19 BACH1 BTB and CNC homology 1, basic leucine zipper transcription factor 1 Blood + 3.38 0.000
20 NAIP NLR family, apoptosis inhibitory protein Blood + 3.34 0.000
21 EPHB6 EPH receptor B6 Blood - 3.30 0.000
22 DICER1 dicer 1, ribonuclease type III Blood + 3.26 0.000
23 MVD mevalonate (diphospho) decarboxylase Blood - 3.26 0.000
24 FBLN2 fibulin 2 Blood - 3.26 0.000
25 FBXL16 F-box and leucine-rich repeat protein 16 Blood - 3.23 0.000
26 CR2 complement component (3d/Epstein Barr virus) receptor 2 Blood - 3.21 0.000
27 PRSS33 protease, serine, 33 Blood - 3.21 0.000
28 FGF13 fibroblast growth factor 13 Blood + 3.20 0.000
29 GNPNAT1 glucosamine-phosphate N-acetyltransferase 1 Blood - 3.19 0.000
30 RTKN2 rhotekin 2 Blood - 3.19 0.000
31 EPHA1 EPH receptor A1 Blood - 3.16 0.000
32 APOL6 apolipoprotein L, 6 Blood + 3.16 0.000
33 CRIP2 cysteine-rich protein 2 Blood - 3.15 0.000
34 C1QB complement component 1, q subcomponent, B chain Blood + 3.15 0.000
35 CARD17 caspase recruitment domain family, member 17 Blood + 3.14 0.000
36 SERINC5 serine incorporator 5 Blood - 3.12 0.000
37 HKDC1 hexokinase domain containing 1 Blood - 3.11 0.000
38 NT5E 5'-nucleotidase, ecto (CD73) Blood - 3.10 0.000
39 LINC00342 long intergenic non-protein coding RNA 342 Blood + 3.10 0.000
40 PMEPA1 prostate transmembrane protein, androgen induced 1 Blood - 3.09 0.000
41 FCGBP Fc fragment of IgG binding protein Blood - 3.07 0.000
42 SALL2 spalt-like transcription factor 2 Blood - 3.06 0.000
43 GPA33 glycoprotein A33 (transmembrane) Blood - 3.02 0.000
44 SLC27A5 solute carrier family 27 (fatty acid transporter), member 5 Blood - 3.00 0.000
Search GEO for disease gene expression data for Pulmonary Tuberculosis.

Pathways for Pulmonary Tuberculosis

Pathways related to Pulmonary Tuberculosis according to GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 TNF TLR2 SLC11A1 PGM1 P2RX7 MBL2
2
Show member pathways
13.72 TNF INHA IL4 IL2 IL18 IL12RB1
3
Show member pathways
13.59 TNF IL4 IL2 IL18 IL12RB1 IL12B
4
Show member pathways
13.45 TNF TLR2 IL4 IL2 IL18 IL12RB1
5
Show member pathways
13.45 TNF IL4 IL2 IL18 IL12RB1 IL12B
6
Show member pathways
13.34 TNF IL4 IL2 IL18 IL12RB1 IL12B
7
Show member pathways
13.25 TNF TLR2 IL4 IL2 IFNGR1 IFNG
8
Show member pathways
13.13 TNF TLR2 P2RX7 MBL2 IL2 IL18
9
Show member pathways
12.9 TNF IL4 IL2 IL18 IL12RB1 IL12B
10 12.89 IL4 IL2 IL12RB1 IL12B IFNGR1 IFNG
11
Show member pathways
12.67 TNF IL2 IL18 IL12RB1 IL12B IL10
12 12.65 TNF TLR2 IL4 IL2 IL10 IFNG
13
Show member pathways
12.62 TNF IL4 IL2 IL10 IFNG
14
Show member pathways
12.58 TNF IL4 IL2 IL18 IL12RB1 IL12B
15
Show member pathways
12.57 TNF IL4 IL2 IFNGR1 IFNG
16
Show member pathways
12.49 IL4 IL2 IL12RB1 IL12B IL10 IFNGR1
17
Show member pathways
12.37 TNF IL4 IL2 IFNG
18
Show member pathways
12.36 TNF TLR2 IL4 IFNG
19
Show member pathways
12.35 TNF IL4 IL2 IL18 IL12B IL10
20
Show member pathways
12.28 TNF TLR2 IL4 IFNGR1 IFNG
21
Show member pathways
12.28 TNF TLR2 IL4 IL12B IL10 IFNGR1
22
Show member pathways
12.25 TNF IL2 IL12B IL10
23 12.23 TNF TLR2 IFNGR1 IFNG
24
Show member pathways
12.23 TNF TLR2 IL4 IL2 IL18 IL12RB1
25
Show member pathways
12.18 IL4 IL2 IL18 IL12B IL10 IFNGR1
26 12.16 VDR TNF TLR2 IL18 IL12B IL10
27 12.11 TNF IL4 IL2 IL10 IFNG
28
Show member pathways
12.1 TNF TLR2 IL4 IFNG
29 12.1 TNF IL4 IL18 IL12B IL10
30 12.07 TNF IL4 IL2 IFNG
31 12.04 TNF TLR2 IL12B IL10 IFNG
32
Show member pathways
12.03 IL4 IL2 IL18 IL12RB1 IL12B IFNG
33 12 IL2 IL12RB1 IL12B IL10 IFNGR1 IFNG
34 11.99 TNF TLR2 IL18 IFNG HLA-DRB1
35
Show member pathways
11.92 TNF TLR2 IL2 IL18 IL12RB1 IL12B
36 11.9 TNF IL4 HLA-DRB1
37 11.88 MBL2 IL10 HLA-DRB1
38
Show member pathways
11.85 TNF IL4 IL2 IFNG
39 11.84 TNF IL2 IL10 IFNG
40 11.83 IL18 IFNGR1 IFNG
41 11.82 IL4 IL2 IFNG
42 11.82 TNF IL4 IL2 IL18 IL12RB1 IL10
43 11.81 TNF IL4 IL2 IL18 IL10 IFNG
44 11.79 TNF IL12B IL10
45 11.71 TNF TLR2 IL18 IL12B
46
Show member pathways
11.7 TNF IL2 IFNG
47 11.7 TNF IL4 IL12B
48
Show member pathways
11.68 TNF IL2 IFNG
49 11.66 TNF TLR2 IL18 IL10 IFNG
50 11.65 TNF IL4 IL18 IL12B IL10

GO Terms for Pulmonary Tuberculosis

Cellular components related to Pulmonary Tuberculosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.9 TNF PGM1 MBL2 INHA IL4 IL2
2 cell surface GO:0009986 9.73 TNF TLR2 MBL2 IL12B HLA-DRB1 ADA
3 external side of plasma membrane GO:0009897 9.43 TNF P2RX7 IL12RB1 IL12B HLA-DRB1 ADA
4 extracellular space GO:0005615 9.36 TNF MBL2 INHA IL4 IL2 IL18

Biological processes related to Pulmonary Tuberculosis according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 9.99 TNF P2RX7 IL2 IFNG
2 response to lipopolysaccharide GO:0032496 9.98 TLR2 SLC11A1 P2RX7 IL10
3 positive regulation of gene expression GO:0010628 9.92 VDR TNF TLR2 SLC11A1 P2RX7 IL4
4 defense response to Gram-positive bacterium GO:0050830 9.91 TNF TLR2 P2RX7 MBL2
5 cellular response to interferon-gamma GO:0071346 9.9 TLR2 IL12RB1 IL12B
6 interferon-gamma-mediated signaling pathway GO:0060333 9.89 IFNGR1 IFNG HLA-DRB1
7 cellular response to organic cyclic compound GO:0071407 9.89 TNF P2RX7 IL18
8 positive regulation of T cell proliferation GO:0042102 9.88 IL4 IL2 IL12B
9 response to organic substance GO:0010033 9.88 TNF P2RX7 IL12B IL10 HP
10 positive regulation of interleukin-6 production GO:0032755 9.87 TNF TLR2 P2RX7
11 extrinsic apoptotic signaling pathway GO:0097191 9.85 TNF P2RX7 IFNG
12 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.85 TNF TLR2 IL18 IL12B
13 positive regulation of B cell proliferation GO:0030890 9.84 IL4 IL2 ADA
14 positive regulation of phagocytosis GO:0050766 9.83 TNF SLC11A1 MBL2
15 lipopolysaccharide-mediated signaling pathway GO:0031663 9.83 TNF TLR2 IL18
16 positive regulation of inflammatory response GO:0050729 9.83 TNF TLR2 IL2 IL18 IL12B
17 positive regulation of cytokine secretion GO:0050715 9.82 TNF P2RX7 IL10
18 natural killer cell activation GO:0030101 9.81 IL2 IL18 IL12B
19 interleukin-12-mediated signaling pathway GO:0035722 9.81 IL12RB1 IL12B IL10 IFNG
20 immune response GO:0006955 9.81 TNF TLR2 SLC11A1 IL4 IL2 IL18
21 positive regulation of interleukin-12 production GO:0032735 9.79 TLR2 IL12B IFNG
22 positive regulation of T cell mediated cytotoxicity GO:0001916 9.77 P2RX7 IL12RB1 IL12B
23 positive regulation of osteoclast differentiation GO:0045672 9.77 TNF IL12B IFNG
24 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.77 IL4 IL2 IL18 IL12B IFNG
25 positive regulation of T cell differentiation GO:0045582 9.76 IL4 IL2 ADA
26 positive regulation of activated T cell proliferation GO:0042104 9.76 IL2 IL18 IL12RB1 IL12B
27 defense response to protozoan GO:0042832 9.75 SLC11A1 IL12B IL10
28 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.73 IFNGR1 IFNG
29 positive regulation of interleukin-17 production GO:0032740 9.73 IL2 IL18 IL12B
30 response to molecule of bacterial origin GO:0002237 9.72 TLR2 IL10
31 negative regulation of interleukin-17 production GO:0032700 9.72 IL12B IFNG
32 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.72 IL18 IL12B
33 positive regulation of isotype switching to IgG isotypes GO:0048304 9.72 IL4 IL2
34 positive regulation of smooth muscle cell apoptotic process GO:0034393 9.72 IL12B IFNG
35 interleukin-23-mediated signaling pathway GO:0038155 9.71 IL12RB1 IL12B
36 endothelial cell apoptotic process GO:0072577 9.71 TNF IL10
37 T-helper 1 type immune response GO:0042088 9.71 IL18 IL12B HLA-DRB1
38 positive regulation of T-helper 17 type immune response GO:2000318 9.7 IL12RB1 IL12B
39 positive regulation of natural killer cell proliferation GO:0032819 9.7 IL18 IL12B
40 positive regulation of MHC class II biosynthetic process GO:0045348 9.7 IL4 IL10
41 positive regulation of T-helper 1 type immune response GO:0002827 9.7 SLC11A1 IL12RB1 IL12B
42 positive regulation of neuroinflammatory response GO:0150078 9.69 TNF IL18
43 positive regulation of memory T cell differentiation GO:0043382 9.69 IL12RB1 IL12B
44 negative regulation of cytokine secretion involved in immune response GO:0002740 9.68 TNF IL10
45 T-helper 1 cell cytokine production GO:0035744 9.68 IL18 IL12B
46 regulation of isotype switching GO:0045191 9.67 IL4 IL10
47 positive regulation of T-helper 17 cell lineage commitment GO:2000330 9.67 IL12RB1 IL12B
48 positive regulation of NK T cell proliferation GO:0051142 9.67 IL18 IL12B
49 positive regulation of tissue remodeling GO:0034105 9.67 IL2 IL18 IL12B
50 receptor biosynthetic process GO:0032800 9.65 TNF IL10

Molecular functions related to Pulmonary Tuberculosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.35 INHA IL4 IL2 IL12B IL10
2 cytokine binding GO:0019955 9.33 IL12RB1 IL12B IFNGR1
3 interleukin-12 receptor binding GO:0005143 9.26 IL12RB1 IL12B
4 cytokine activity GO:0005125 9.23 TNF INHA IL4 IL2 IL18 IL12B
5 protein binding GO:0005515 10.25 VDR TNF TLR2 PGM1 P2RX7 NAT2

Sources for Pulmonary Tuberculosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....